Related Experiment Video

Updated: Jun 4, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide

Massimo Offidani1, Laura Corvatta, Claudia Polloni

  • 1Clinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Ancona, Italy. m.offidani@ospedaliriuniti.marche.it

Leukemia & Lymphoma
|February 23, 2011
PubMed

Insights

Thalidomide-treated multiple myeloma patients face severe infection risks, particularly those with high tumor burden. Primary antibiotic prophylaxis is recommended for high-risk individuals, though infections did not impact overall survival.

Area of Science:

  • Hematology
  • Oncology
  • Infectious Diseases

Background:

  • Infectious complications significantly impact outcomes in multiple myeloma (MM) patients.
  • Thalidomide-containing regimens are increasingly used for MM, but data on infection risks are limited.

Purpose of the Study:

  • To assess the incidence, characteristics, and outcomes of severe infections in MM patients treated with thalidomide.
  • To identify risk factors for severe infections and evaluate the role of antibiotic prophylaxis.
  • To determine the effect of severe infections on progression-free survival (PFS) and overall survival (OS).

Main Methods:

  • Retrospective study of 202 MM patients receiving thalidomide-containing regimens.
  • Analysis of infection timing, type, and patient outcomes.
  • Multivariate analysis to identify risk factors and assess prophylaxis effectiveness.

Main Results:

  • 19% of patients developed severe infections, primarily pneumonia, during induction therapy.
  • High monoclonal component (>3 g/dL) and low platelets (<130,000/μL) were associated with increased infection risk.
  • Primary antibiotic prophylaxis reduced infection risk in patients with both risk factors.

Conclusions:

  • MM patients on thalidomide with high tumor burden are at high risk for severe infections.
  • Antibiotic prophylaxis is beneficial for high-risk patients, but its necessity in others is unclear.
  • Severe infections did not significantly affect PFS or OS in this cohort.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...